报告治疗发现长期减轻发作是抗发作药物有效性的生物标志物. Rapport Therapeutics finds long episode reductions valid as a biomarker for anti-seizure drug efficacy.

Rapport Therapeutics 提供的数据显示，长发作 （LE） 减少 30% 与临床癫痫发作减少 50% 或更多有关，验证了 LE 作为概念验证研究的生物标志物。 Rapport Therapeutics presented data showing that a 30% reduction in long episodes (LEs) linked to a 50% or greater reduction in clinical seizures, validating LEs as a biomarker for proof-of-concept studies. 这一结论为评估RAP-219等抗缉获药物的功效确定了新的基准。 This finding sets a new benchmark for evaluating the efficacy of anti-seizure medications like RAP-219. 该公司将LE频率作为主要终点,对焦点癫痫进行第二阶段a试验,预计2025年中期将报告数据。 The company's Phase 2a trial in focal epilepsy, using LE frequency as a primary endpoint, is expected to report data in mid-2025.